NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
30.80
+0.40 (1.32%)
Dec 20, 2024, 4:00 PM EST - Market closed

NovoCure Statistics

Total Valuation

NovoCure has a market cap or net worth of $3.33 billion. The enterprise value is $3.05 billion.

Market Cap 3.33B
Enterprise Value 3.05B

Important Dates

The last earnings date was Wednesday, October 30, 2024, before market open.

Earnings Date Oct 30, 2024
Ex-Dividend Date n/a

Share Statistics

NovoCure has 108.20 million shares outstanding. The number of shares has increased by 1.49% in one year.

Current Share Class 108.20M
Shares Outstanding 108.20M
Shares Change (YoY) +1.49%
Shares Change (QoQ) +0.51%
Owned by Insiders (%) 8.95%
Owned by Institutions (%) 86.35%
Float 98.51M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 5.73
Forward PS 5.23
PB Ratio 9.23
P/TBV Ratio 9.24
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 5.28
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.49, with a Debt / Equity ratio of 1.87.

Current Ratio 1.49
Quick Ratio 1.43
Debt / Equity 1.87
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -17.55

Financial Efficiency

Return on equity (ROE) is -39.70% and return on invested capital (ROIC) is -9.29%.

Return on Equity (ROE) -39.70%
Return on Assets (ROA) -7.93%
Return on Capital (ROIC) -9.29%
Revenue Per Employee $397,617
Profits Per Employee -$103,086
Employee Count 1,453
Asset Turnover 0.49
Inventory Turnover 3.57

Taxes

In the past 12 months, NovoCure has paid $35.29 million in taxes.

Income Tax 35.29M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +125.97% in the last 52 weeks. The beta is 0.76, so NovoCure's price volatility has been lower than the market average.

Beta (5Y) 0.76
52-Week Price Change +125.97%
50-Day Moving Average 21.04
200-Day Moving Average 18.27
Relative Strength Index (RSI) 64.24
Average Volume (20 Days) 1,948,257

Short Selling Information

The latest short interest is 5.63 million, so 5.21% of the outstanding shares have been sold short.

Short Interest 5.63M
Short Previous Month 5.67M
Short % of Shares Out 5.21%
Short % of Float 5.72%
Short Ratio (days to cover) 6.23

Income Statement

In the last 12 months, NovoCure had revenue of $577.74 million and -$149.78 million in losses. Loss per share was -$1.39.

Revenue 577.74M
Gross Profit 442.26M
Operating Income -150.19M
Pretax Income -141.13M
Net Income -149.78M
EBITDA -140.61M
EBIT -150.19M
Loss Per Share -$1.39
Full Income Statement

Balance Sheet

The company has $959.90 million in cash and $675.63 million in debt, giving a net cash position of $284.27 million or $2.63 per share.

Cash & Cash Equivalents 959.90M
Total Debt 675.63M
Net Cash 284.27M
Net Cash Per Share $2.63
Equity (Book Value) 360.78M
Book Value Per Share 3.34
Working Capital 360.27M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$37.48 million and capital expenditures -$40.73 million, giving a free cash flow of -$78.21 million.

Operating Cash Flow -37.48M
Capital Expenditures -40.73M
Free Cash Flow -78.21M
FCF Per Share -$0.72
Full Cash Flow Statement

Margins

Gross margin is 76.55%, with operating and profit margins of -26.00% and -25.93%.

Gross Margin 76.55%
Operating Margin -26.00%
Pretax Margin -19.82%
Profit Margin -25.93%
EBITDA Margin -24.34%
EBIT Margin -26.00%
FCF Margin n/a

Dividends & Yields

NovoCure does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -1.49%
Shareholder Yield -1.49%
Earnings Yield -4.49%
FCF Yield -2.35%
Dividend Details

Analyst Forecast

The average price target for NovoCure is $33.40, which is 8.44% higher than the current price. The consensus rating is "Buy".

Price Target $33.40
Price Target Difference 8.44%
Analyst Consensus Buy
Analyst Count 5
Revenue Growth Forecast (5Y) 20.20%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

NovoCure has an Altman Z-Score of 0.37 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 0.37
Piotroski F-Score 4